Loading…

Temporal trend and risk factors for mother-to-child HIV transmission in Southern Brazil, 2007-2017

Abstract Background HIV infection affects women of childbearing age, and unplanned pregnancies among those infected are prevalent. This fact increases the potential risk for mother-to-child transmission during pregnancy, childbirth or postpartum through breastfeeding. The Brazilian Ministry of Healt...

Full description

Saved in:
Bibliographic Details
Published in:European journal of public health 2020-09, Vol.30 (Supplement_5)
Main Authors: Schuelter-Trevisol, F, Vaica, I, Cunga, Armando, Moehlecke Iser, B, Bittencourt, B, Augusto da Rosa, C M, Cremona Parma, G, Trevisol, D J
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background HIV infection affects women of childbearing age, and unplanned pregnancies among those infected are prevalent. This fact increases the potential risk for mother-to-child transmission during pregnancy, childbirth or postpartum through breastfeeding. The Brazilian Ministry of Health recommends anti-HIV testing for all pregnant women. Access to antiretroviral therapy is available through prenatal and maternity care, and breastfeeding is contraindicated. The detection rate of pregnant women living with HIV in Brazil has increased by 23.8% in the last ten years. The aim of this study was to estimate the incidence of seroconversion of HIV infection in children exposed to mother-to-child transmission and examine associated risk factors for the period 2007-2017 in Santa Catarina, Brazil. Methods A historical cohort study was conducted using secondary data related to the notifications of HIV-infected pregnant woman and follow-up of HIV-exposed infants. Odds ratios were used to estimate the risk of infection. Results We identified 5,554 HIV-infected pregnant women and 4,559 HIV-exposed infants, 130 of whom had confirmed seroconversion, which corresponds to a rate of 2.9%. Antiretroviral use during pregnancy [OR = 9.31 (5.97-14.52) p 
ISSN:1101-1262
1464-360X
DOI:10.1093/eurpub/ckaa166.836